Want to join the conversation?
Biopharmaceutical company $REGN posted almost flat 2Q16 results. $REGN said net income rose 0.51% to $196MM, or $1.69 per share from $195MM, or $1.69 per share a year ago. Total revenues rose 21.42% to $1.21Bil versus a year ago, helped by inclusion of Sanofi and Bayer collaboration revenues. Excluding items $REGN earned $2.82 per share.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!
$SGY is expected to achieve $6.17 price target in next year, with a minimum target of $3.00, due to the price increase of 27.85% to $6.29 during the last trading session.